Thrombosis Prevention by Coagulation and Platelet Aggregation Inhibitors, in Hyperlipemic Rats^[*)]

Summary

Phenylbutazone, oxyphenbutazone, and sulfinpyrazone were equally effective at the dosage of 100 mg/kg (per os) in inhibiting thrombin- and ADP-induced platelet aggregation in hyperlipemic rats, and in preventing the development of thrombosis initiated by the intravenous injection of an endotoxin. Despite a slight anticoagulant effect of these substances, their antithrombotic activity appears to be due mostly to inhibition of platelet aggregation.

Thrombosis in hyperlipemic rats could also be prevented by a dicoumarol derivative, acenocoumarin, which only inhibits coagulation. Therefore, both platelet aggregation and fibrin formation appear to be essential for the occurrence of large thrombi under these conditions. Nevertheless, although acenocoumarin has no direct effect on platelet aggregation, it could indirectly affect this phenomenon by blocking the formation of thrombin, which is suspected of being the agent responsible for initiating thrombosis in hyperlipemic rats.

Low doses of phenylbutazone and acenocoumarin, in condition, which when given alone were ineffective in inhibiting thrombosis, could decrease the severity of thrombosis by 33%. The substance GP45840, when added in vitro to platelet-rich plasma as well as given per os to hyperlipemic rats, was no more effective than sulfinpyrazone in inhibiting platelet aggregation. Nevertheless, this substance was significantly more efficient in reducing thrombosis than was sulfinpyrazone, apparently through some additional anticoagulant activity. The results of these experiments suggest that it could be beneficial to affect both coagulation and platelet aggregation in order to satisfactorily prevent thrombosis.

^*) Presented in part at the 54th Annual Meeting of the Federation of American Societies for Experimental Biology, Atlantic City, April 15, 1970.

^**) Scholar of the Medical Research Council.

^***) Fellow of the Jean-Louis Lévesque Foundation.

• References

• 1 Bizzozero G. Über einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Arch. path. Anat 90: 261 1882;
• 2 Wessler S. Stasis, hypercoagulability, and thrombosis. Fed. Proc 22: 1366 1963;
• 3 Rodman N. F, Mason R. G, Brinkhous K. M. Some pathogenetic mechanisms of white thrombus formation: agglutination and self-destruction of the platelet. Fed. Proc 22: 1356 1963;
• 4 Mustard J. F. The relationship between the structure of a thrombus or a hemostatic plug and the mechanisms involved in its formation. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl 28: 57 1968;
• 5 Renaud S. Thrombosis and hepatic infarct as elicited in hyperlipemic rats by bacterial endotoxin. Lab. Invest 12: 1078 1963;
• 6 Renaud S. Endotoxin-indnced hepatic vein thrombosis in hyperlipemic rats. Sequence of events. Lab. Invest 14: 424 1965;
• 7 Renaud S. Thrombotic, atherosclerotic and lipemic effects of dietary fats in the rat. Angiology 20: 657 1969;
• 8 Renaud S, Godu J. Induction of large thrombi in hyperlipemic rats by epinephrine and endotoxin. Lab. Invest 21: 512 1969;
• 9 Packham M. A, Warrior E. S, Glynn M. F, Senyi A. S, Mustard J. F. Alteration of the response of platelets to surface stimuli by pyrazole compounds. J. exp. Med 126: 171 1967;
• 10 Renaud S. Anticoagulants in the prevention of endotoxin-induced phlebothrombosis in rat. J. Lab. clin. Med 66: 235 1965;
• 11 Renaud S, Allard G. Influence of dietary factors on certain blood parameters and the production of endotoxin-initiated-phlebothrombosis in rat. Canad. J. Physiol. Pharmacol 43: 359 1965;
• 12 Renaud S. Jugular vein technique for blood collection and intravenous injection in the rat. Lab. Animal Care 19: 664 1969;
• 13 Renaud S. The recalcification plasma clotting time. A valuable general clotting test in man and rats. Canad. J. Physiol. Pharmacol 47: 689 1969;
• 14 Renaud S, Godu J. Thrombosis prevention by acetylsalicylic acid in hyperlipemic rats. Canad. med. Assoc. J 103: 1037 1970;
• 15 Peterson J, Zucker M. B. The effect of adenosine monophosphate. Arcaine and antiinflammatory agents on thrombosis and platelet function in rabbits. Thrombos. Diathes. haemorrh (Stuttg) 23: 148 1970;
• 16 Smythe H. A, Ogryzlo M. A, Murphy E. A, Mustard J. F. The effect of sulfinpyrazone (anturan) on platelet economy and blood coagulation in man. Canad. med. Ass. J 92: 818 1965;
• 17 Domenjoz R. The pharmacology of phenylbutazone analogues. Ann. N.Y. Acad. Sci 86: 263 1960;
• 18 Renaud S, Allard G, Latour J. G. The prevention by glucocorticoids of the endotoxin- initiated thrombosis in rat, in relation to fibrinolysis, coagulation and lipemia. Amer. Heart J 72: 797 1966;
• 19 Sullivan J. M, Harken D. E, Zorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. New Engl. J. Med 279: 576 1968;